

Amos D Korczyn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7240772/publications.pdf>

Version: 2024-02-01

569
papers

32,677
citations

8172

76
h-index

5986

160
g-index

594
all docs

594
docs citations

594
times ranked

28170
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. <i>Neurology</i> , 2005, 65, 1863-1872.	1.5	4,604
2	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1689-1707.	2.2	2,497
3	A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. <i>New England Journal of Medicine</i> , 2000, 342, 1484-1491.	13.9	1,467
4	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007, 22, 2314-2324.	2.2	885
5	Construction of freezing of gait questionnaire for patients with Parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2000, 6, 165-170.	1.1	669
6	Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. <i>Nature Genetics</i> , 2013, 45, 825-830.	9.4	589
7	Post-stroke dementia – a comprehensive review. <i>BMC Medicine</i> , 2017, 15, 11.	2.3	442
8	X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. <i>Nature Genetics</i> , 2008, 40, 776-781.	9.4	397
9	Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. <i>Brain</i> , 2008, 131, 1831-1844.	3.7	340
10	Freezing of gait in patients with advanced Parkinson's disease. <i>Journal of Neural Transmission</i> , 2001, 108, 53-61.	1.4	338
11	Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. <i>Nature Genetics</i> , 2012, 44, 1188-1190.	9.4	333
12	ApoE4: an emerging therapeutic target for Alzheimer's disease. <i>BMC Medicine</i> , 2019, 17, 64.	2.3	282
13	Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study. <i>Movement Disorders</i> , 1998, 13, 39-45.	2.2	262
14	CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury. <i>Cell</i> , 2019, 176, 1143-1157.e13.	13.5	249
15	Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 523-526.	0.6	247
16	The value of muscle exercise in patients with amyotrophic lateral sclerosis. <i>Journal of the Neurological Sciences</i> , 2001, 191, 133-137.	0.3	242
17	Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. <i>American Journal of Human Genetics</i> , 2019, 105, 267-282.	2.6	237
18	PRRT2 Mutations Cause Benign Familial Infantile Epilepsy and Infantile Convulsions with Choreoathetosis Syndrome. <i>American Journal of Human Genetics</i> , 2012, 90, 152-160.	2.6	234

#	ARTICLE	IF	CITATIONS
19	Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?. BMC Medicine, 2018, 16, 34.	2.3	232
20	High-value space analyzed diffusion-weighted MRI: Application to multiple sclerosis. Magnetic Resonance in Medicine, 2002, 47, 115-126.	1.9	228
21	Subjective memory complaints in elders: depression, anxiety, or cognitive decline?. Acta Neurologica Scandinavica, 2013, 127, 344-350.	1.0	222
22	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement Disorders, 2007, 22, 2409-2417.	2.2	221
23	Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole. Movement Disorders, 2007, 22, 2398-2404.	2.2	214
24	Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects. BMC Medicine, 2017, 15, 41.	2.3	212
25	A Homozygous Mutation in Human PRICKLE1 Causes an Autosomal-Recessive Progressive Myoclonus Epilepsy-Ataxia Syndrome. American Journal of Human Genetics, 2008, 83, 572-581.	2.6	199
26	Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. Journal of Neural Transmission, 2000, 107, 59-71.	1.4	197
27	Mixed Dementia—the Most Common Cause of Dementia. Annals of the New York Academy of Sciences, 2002, 977, 129-134.	1.8	190
28	Mutation in codon 200 of scrapie amyloid precursor gene linked to Creutzfeldt-Jakob disease in Sephardic Jews of Libyan and non-Libyan origin. Lancet, The, 1990, 336, 637-638.	6.3	187
29	Antiphospholipid antibodies permeabilize and depolarize brain synaptoneuroosomes. Lupus, 1999, 8, 127-133.	0.8	181
30	Consensus statement for diagnosis of subcortical small vessel disease. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 6-25.	2.4	173
31	Epilepsy and mental retardation limited to females: an under-recognized disorder. Brain, 2008, 131, 918-927.	3.7	172
32	Galantamine treatment of vascular dementia. Neurology, 2007, 69, 448-458.	1.5	167
33	<i>APOE</i> genotype is a major predictor of long-term progression of disability in MS. Neurology, 2001, 56, 312-316.	1.5	162
34	Sexual Dysfunction in Parkinson's Disease. Journal of Sex and Marital Therapy, 2004, 30, 95-105.	1.0	160
35	Computer-Based, Personalized Cognitive Training versus Classical Computer Games: A Randomized Double-Blind Prospective Trial of Cognitive Stimulation. Neuroepidemiology, 2011, 36, 91-99.	1.1	158
36	Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa. Clinical Neuropharmacology, 2000, 23, 324-330.	0.2	153

#	ARTICLE	IF	CITATIONS
37	The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac β and β^2 myosin heavy chain genes on chromosome 14q11.2-q13. <i>Human Molecular Genetics</i> , 1995, 4, 429-434.	1.4	152
38	Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. <i>Movement Disorders</i> , 2006, 21, 1844-1850.	2.2	145
39	Depression and dementia. <i>Journal of the Neurological Sciences</i> , 2009, 283, 139-142.	0.3	139
40	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study. <i>Movement Disorders</i> , 1998, 13, 46-51.	2.2	135
41	Vascular dementia. <i>Journal of the Neurological Sciences</i> , 2012, 322, 2-10.	0.3	131
42	Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. <i>Journal of Neural Transmission Parkinson's Disease and Dementia Section</i> , 1992, 4, 277-282.	1.2	128
43	Genetic Architecture of Idiopathic Generalized Epilepsy: Clinical Genetic Analysis of 55 Multiplex Families. <i>Epilepsia</i> , 2004, 45, 467-478.	2.6	128
44	Autonomic impairment in amyotrophic lateral sclerosis. <i>Current Opinion in Neurology</i> , 2005, 18, 487-493.	1.8	126
45	Kinematic analysis of upper limb trajectories in Parkinson's disease. <i>Experimental Neurology</i> , 1992, 118, 215-226.	2.0	124
46	Idiopathic intracranial hypertension. <i>Neurology</i> , 2004, 63, 1737-1739.	1.5	120
47	Association Between Ocular Pressure and Certain Health Parameters. <i>Ophthalmology</i> , 1984, 91, 311-314.	2.5	119
48	Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. <i>Lupus</i> , 2003, 12, 436-442.	0.8	119
49	Life-long history of injuries related to seizures. <i>Epilepsy Research</i> , 1999, 34, 123-127.	0.8	118
50	Identification of multiple loci for Alzheimer disease in a consanguineous Israeli-Arab community. <i>Human Molecular Genetics</i> , 2003, 12, 415-422.	1.4	117
51	ACE, MTHFR, Factor V Leiden, and APOE Polymorphisms in Patients With Vascular and Alzheimer's Dementia. <i>Stroke</i> , 1998, 29, 1401-1404.	1.0	116
52	Acute Infection as a Risk Factor for Ischemic Stroke. <i>Stroke</i> , 1996, 27, 2204-2206.	1.0	116
53	Creutzfeldt-Jacob disease associated with the PRNP codon 200LYS mutation: An analysis of 45 families. <i>European Journal of Epidemiology</i> , 1991, 7, 477-486.	2.5	115
54	Vascular parkinsonism's characteristics, pathogenesis and treatment. <i>Nature Reviews Neurology</i> , 2015, 11, 319-326.	4.9	113

#	ARTICLE	IF	CITATIONS
55	Genetic epilepsy with febrile seizures plus. <i>Neurology</i> , 2017, 89, 1210-1219.	1.5	112
56	Female sexuality in multiple sclerosis: the multidimensional nature of the problem and the intervention. <i>Acta Neurologica Scandinavica</i> , 2010, 121, 289-301.	1.0	109
57	Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model.. <i>Journal of Clinical Investigation</i> , 1997, 100, 613-619.	3.9	108
58	EEG in demented and non-demented parkinsonian patients. <i>Acta Neurologica Scandinavica</i> , 1988, 78, 1-5.	1.0	104
59	Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2004, 111, 1447-1453.	1.4	100
60	Use of the Virtual Action Planning Supermarket for the Diagnosis of Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 301-309.	0.7	100
61	Management of mild cognitive impairment (MCI): The need for national and international guidelines. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 579-594.	1.3	100
62	The amyloid cascade hypothesis. <i>Alzheimer's and Dementia</i> , 2008, 4, 176-178.	0.4	98
63	The pupillary effects of oploids. <i>Life Sciences</i> , 1983, 33, 495-509.	2.0	96
64	Efficacy and safety of a once-a-day formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1186-1194.	1.3	96
65	Early onset dementia: clinical and social aspects. <i>International Psychogeriatrics</i> , 2009, 21, 631-636.	0.6	94
66	Familial neonatal seizures in 36 families: Clinical and genetic features correlate with outcome. <i>Epilepsia</i> , 2015, 56, 1071-1080.	2.6	94
67	Presenile Dementia in Israel. <i>Archives of Neurology</i> , 1986, 43, 26-29.	4.9	92
68	Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. <i>Annals of Neurology</i> , 1999, 46, 115-118.	2.8	92
69	Antibodies to brain antigens following stroke. <i>Neurology</i> , 2001, 56, 529-530.	1.5	90
70	Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 119, 577-584.	1.0	90
71	Association of APOE ϵ 4 allele with survival in amyotrophic lateral sclerosis. <i>Journal of the Neurological Sciences</i> , 2001, 190, 17-20.	0.3	87
72	Practice parameters and technology assessments: What they are, what they are not, and why you should care. <i>Neurology</i> , 2009, 73, 1336-1337.	1.5	87

#	ARTICLE	IF	CITATIONS
73	What are the correlates of cognition and participation to return to work after first ever mild stroke?. Topics in Stroke Rehabilitation, 2015, 22, 317-325.	1.0	87
74	Ancestral Origins and Worldwide Distribution of the PRNP 200K Mutation Causing Familial Creutzfeldt-Jakob Disease. American Journal of Human Genetics, 1999, 64, 1063-1070.	2.6	85
75	Low-dose Clozapine in the Treatment of Levodopa-Induced Mental Disturbances in Parkinson's Disease. Neurology, 1995, 45, 432-434.	1.5	81
76	Phosphatidylserine Containing ω -3 Fatty Acids May Improve Memory Abilities in Non-Demented Elderly with Memory Complaints: A Double-Blind Placebo-Controlled Trial. Dementia and Geriatric Cognitive Disorders, 2010, 29, 467-474.	0.7	81
77	Smoking and tea consumption delay onset of Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 41-46.	1.1	80
78	<i>LGII</i> mutations in temporal lobe epilepsies. Neurology, 2004, 62, 1115-1119.	1.5	79
79	Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology, 1996, 47, 785-788.	1.5	78
80	Cognitive Decline After Stroke. Stroke, 2013, 44, 1433-1435.	1.0	77
81	The diabetic brain and cognition. Journal of Neural Transmission, 2017, 124, 1431-1454.	1.4	77
82	Towards the concept of disease-modifier in post-stroke or vascular cognitive impairment: a consensus report. BMC Medicine, 2017, 15, 107.	2.3	77
83	Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (<i>Vicia faba</i>) consumption.. Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 725-727.	0.9	76
84	Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurologica Scandinavica, 2003, 108, 368-373.	1.0	76
85	Failure of aspirin treatment after stroke.. Stroke, 1994, 25, 275-277.	1.0	74
86	Use of the Selective Serotonin 3 Receptor Antagonist Ondansetron in the Treatment of Neuroleptic-Induced Tardive Dyskinesia. American Journal of Psychiatry, 2000, 157, 287-289.	4.0	74
87	Autonomic function in mice lacking α 5 neuronal nicotinic acetylcholine receptor subunit. Journal of Physiology, 2002, 542, 347-354.	1.3	73
88	The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. Progress in Neurobiology, 2002, 68, 341-360.	2.8	72
89	ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin). Stroke, 2017, 48, 1262-1270.	1.0	71
90	Demyelinating peripheral neuropathy in Creutzfeldt-Jakob disease. Muscle and Nerve, 1992, 15, 1234-1239.	1.0	70

#	ARTICLE	IF	CITATIONS
91	Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. <i>Lupus</i> , 2002, 11, 736-743.	0.8	70
92	The Tel Aviv Stroke Registry. <i>Stroke</i> , 1996, 27, 1770-1773.	1.0	70
93	Mild cognitive impairment: Conceptual, assessment, ethical, and social issues. <i>Clinical Interventions in Aging</i> , 2008, Volume 3, 413-420.	1.3	69
94	Myoclonus epilepsy and ataxia due to <i>KCNC1</i> mutation: Analysis of 20 cases and channel properties. <i>Annals of Neurology</i> , 2017, 81, 677-689.	2.8	69
95	Translational research on reserve against neurodegenerative disease: consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer's Association Reserve, Resilience and Protective Factors Professional Interest Area working groups. <i>BMC Medicine</i> , 2019, 17, 47.	2.3	69
96	Quality of sexual life in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2002, 8, 243-246.	1.1	68
97	Clinical characteristics of neuroleptic-induced parkinsonism. <i>Journal of Neural Transmission</i> , 2001, 108, 1299-1308.	1.4	67
98	Sequence Variants in SLC6A3, DRD2, and BDNF Genes and Time to Levodopa-Induced Dyskinesias in Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2014, 53, 183-188.	1.1	67
99	Impact of first-ever mild stroke on participation at 3 and 6 month post-event: the TABASCO study. <i>Disability and Rehabilitation</i> , 2015, 37, 667-673.	0.9	67
100	The effects of <i>APOE</i> genotype on age at onset and progression of neurodegenerative diseases. <i>Neurology</i> , 2001, 57, 1482-1485.	1.5	65
101	Prevalence of Alzheimer's type dementia in an elderly Arab population. <i>European Journal of Neurology</i> , 2001, 8, 119-123.	1.7	65
102	Clinical heterogeneity and unusual presentations of Creutzfeldt-Jakob disease in Jewish patients with the PRNP codon 200 mutation.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993, 56, 1109-1112.	0.9	64
103	M1 Agonists for the Treatment of Alzheimer's Disease.. <i>Annals of the New York Academy of Sciences</i> , 1996, 777, 189-196.	1.8	64
104	The prevention of the dementia epidemic. <i>Journal of the Neurological Sciences</i> , 2007, 257, 2-4.	0.3	64
105	A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 459-467.	0.6	64
106	Hyperactivity in a mouse model of the antiphospholipid syndrome. <i>Lupus</i> , 2001, 10, 496-499.	0.8	63
107	Stress and epilepsy: the Gulf war experience. <i>Seizure: the Journal of the British Epilepsy Association</i> , 1994, 3, 135-139.	0.9	62
108	Fatal insomnia in a case of familial Creutzfeldt-Jakob disease with the codon 200 <i>Lys</i> mutation. <i>Neurology</i> , 1996, 46, 758-761.	1.5	62

#	ARTICLE	IF	CITATIONS
109	Dementia and Antiphospholipid Antibodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 36-38.	0.7	61
110	Magnetic resonance imaging in cerebrotendinous xanthomatosis: A prospective clinical and neuroradiological study. <i>Journal of the Neurological Sciences</i> , 1994, 122, 102-108.	0.3	60
111	White matter changes in multiple sclerosis: correlation of q-space diffusion MRI and 1H MRS. <i>Magnetic Resonance Imaging</i> , 2005, 23, 703-710.	1.0	60
112	Sound lateralization and interaural discrimination.. <i>Hearing Research</i> , 2000, 143, 29-42.	0.9	58
113	Lupus anticoagulant and late onset seizures. <i>Acta Neurologica Scandinavica</i> , 1989, 79, 114-118.	1.0	57
114	Hypersensitivity Vasculitis and Systemic Lupus Erythematosus Induced by Anticonvulsants. <i>Clinical Neuropharmacology</i> , 1993, 16, 19-29.	0.2	57
115	Kinematic properties of upper limb trajectories in idiopathic torsion dystonia.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 58, 312-319.	0.9	57
116	A History of Migraine Is Not A Risk Factor to Develop an Ischemic Stroke in the Elderly. <i>Headache</i> , 2001, 41, 399-401.	1.8	57
117	Stroke in Hospitalized Patients: Are There Special Risk Factors?. <i>Cerebrovascular Diseases</i> , 2002, 13, 127-131.	0.8	57
118	Ropinirole in Gilles de la Tourette syndrome. <i>Neurology</i> , 2004, 62, 1626-1627.	1.5	57
119	Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience. <i>Clinical Neuropharmacology</i> , 2017, 40, 268-272.	0.2	57
120	Microembolism, silent brain infarcts and dementia. <i>Journal of the Neurological Sciences</i> , 2012, 322, 250-253.	0.3	55
121	Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2). <i>Epilepsy and Behavior</i> , 2013, 28, 283-302.	0.9	55
122	An updated diagnostic approach to subtype definition of vascular parkinsonism – Recommendations from an expert working group. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 9-16.	1.1	55
123	The nigrostriatal dopaminergic system in familial early onset parkinsonism with <i>parkin</i> mutations. <i>Neurology</i> , 2001, 56, 1759-1762.	1.5	54
124	EEG changes during long-term treatment with donepezil in Alzheimer's disease patients. <i>Journal of Neural Transmission</i> , 2001, 108, 1167-1173.	1.4	53
125	A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. <i>Journal of Neural Transmission</i> , 2002, 109, 489-501.	1.4	53
126	Antibodies to Cholinergic Neurons in Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 1988, 51, 479-485.	2.1	52

#	ARTICLE	IF	CITATIONS
127	Evaluation of the Short Parkinson's Evaluation Scale. <i>Clinical Neuropharmacology</i> , 1997, 20, 322-337.	0.2	51
128	Parkinsonism in Patients with Lacunar Infarcts of the Basal Ganglia. <i>European Neurology</i> , 1995, 35, 46-49.	0.6	50
129	Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. <i>Journal of the Neurological Sciences</i> , 2002, 203-204, 81-84.	0.3	50
130	Gender effect on time to levodopa-induced dyskinesias. <i>Journal of Neurology</i> , 2011, 258, 2048-2053.	1.8	50
131	Gender differences in lay persons' beliefs and knowledge about Alzheimer's disease (AD): A national representative study of Israeli adults. <i>Archives of Gerontology and Geriatrics</i> , 2013, 56, 400-404.	1.4	50
132	Disorders of the Oral Cavity in Parkinson's Disease and Parkinsonian Syndromes. <i>Parkinson's Disease</i> , 2015, 2015, 1-6.	0.6	50
133	Mechanical ventilation in stroke patients—is it worthwhile?. <i>Neurology</i> , 1996, 47, 657-659.	1.5	49
134	West Nile Encephalitis in Israel, 1999: The New York Connection. <i>Emerging Infectious Diseases</i> , 2001, 7, 659-661.	2.0	49
135	Hyperactivity in rats following postnatal anoxia. <i>Behavioural Brain Research</i> , 1983, 7, 379-382.	1.2	48
136	Broad Phenotypic Heterogeneity due to a Novel <i>SCN1A</i> Mutation in a Family With Genetic Epilepsy With Febrile Seizures Plus. <i>Journal of Child Neurology</i> , 2014, 29, 221-226.	0.7	48
137	Do Silent Brain Infarctions Predict the Development of Dementia After First Ischemic Stroke?. <i>Stroke</i> , 1996, 27, 904-905.	1.0	48
138	Mechanisms of syncope in glossopharyngeal neuralgia. <i>Electroencephalography and Clinical Neurophysiology</i> , 1986, 63, 231-235.	0.3	47
139	EEG Frequency Analysis in Demented and Nondemented Parkinsonian Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 1994, 5, 23-28.	0.7	47
140	APOE- ϵ 4 in Patients with Alzheimer Disease and Vascular Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 1996, 10, 189-191.	0.6	47
141	Preliminary Observations on APOE ϵ 4 Allele and Progression of Disability in Multiple Sclerosis. <i>Archives of Neurology</i> , 1999, 56, 1484.	4.9	47
142	High b value q-space-analyzed diffusion MRI in vascular dementia: A preliminary study. <i>Journal of the Neurological Sciences</i> , 2002, 203-204, 235-239.	0.3	47
143	Predictors for Poststroke Outcomes: The Tel Aviv Brain Acute Stroke Cohort (TABASCO) Study Protocol. <i>International Journal of Stroke</i> , 2012, 7, 341-347.	2.9	47
144	Epilepsy subtype-specific copy number burden observed in a genome-wide study of 17,458 subjects. <i>Brain</i> , 2020, 143, 2106-2118.	3.7	47

#	ARTICLE	IF	CITATIONS
145	Torsion dystonia in israel. <i>Annals of Neurology</i> , 1980, 8, 387-391.	2.8	46
146	Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel. <i>Neuromuscular Disorders</i> , 1997, 7, S38-S40.	0.3	46
147	Periodic lateralized epileptiform discharges (PLEDs) following stroke are associated with metabolic abnormalities. <i>Electroencephalography and Clinical Neurophysiology</i> , 1997, 102, 295-298.	0.3	46
148	Incidence of dementia in patients with subjective memory complaints. <i>International Psychogeriatrics</i> , 2005, 17, 265-273.	0.6	46
149	Neuropsychological evaluation of late-onset post-radiotherapy encephalopathy: a comparison with vascular dementia. <i>Journal of the Neurological Sciences</i> , 2005, 229-230, 195-200.	0.3	46
150	Only White Matter Hyperintensities Predicts Post-Stroke Cognitive Performances Among Cerebral Small Vessel Disease Markers: Results from the TABASCO Study. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1293-1299.	1.2	46
151	Prediction of binaural click lateralization by brainstem auditory evoked potentials. <i>Hearing Research</i> , 1990, 49, 347-359.	0.9	45
152	Basal Ganglia Lacunes and Parkinsonism. <i>Neuroepidemiology</i> , 1994, 13, 108-112.	1.1	45
153	The A677V Methylenetetrahydrofolate Reductase Gene Polymorphism and Carotid Atherosclerosis. <i>Stroke</i> , 1999, 30, 2180-2182.	1.0	45
154	Oculopharyngeal MD among Bukhara Jews is due to a founder (GCG) ⁹ mutation in the PABP2 gene. <i>Neurology</i> , 2000, 55, 1267-1270.	1.5	45
155	A new clinical and molecular form of Unverricht-Lundborg disease localized by homozygosity mapping. <i>Brain</i> , 2005, 128, 652-658.	3.7	45
156	Release of platelet 5-hydroxytryptamine by plasma taken from patients during and between migraine attacks. <i>Pain</i> , 1976, 2, 315-318.	2.0	44
157	Denervation, supersensitivity and muscarinic receptors in the cat iris. <i>Biochemical Pharmacology</i> , 1979, 28, 1513-1518.	2.0	44
158	Clinical features of oculopharyngeal muscular dystrophy among Bukhara Jews. <i>Neuromuscular Disorders</i> , 1993, 3, 575-577.	0.3	44
159	Fasting Headache, Weight Loss, and Dehydration. <i>Headache</i> , 1999, 39, 225-227.	1.8	44
160	Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. <i>Acta Neurologica Scandinavica</i> , 2003, 107, 252-255.	1.0	44
161	A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. <i>Alzheimer's and Dementia</i> , 2009, 5, 85-92.	0.4	44
162	Diabetes and the brain: issues and unmet needs. <i>Neurological Sciences</i> , 2014, 35, 995-1001.	0.9	44

#	ARTICLE	IF	CITATIONS
163	Brainstem lesions and click lateralization in patients with multiple sclerosis. <i>Hearing Research</i> , 1995, 82, 109-124.	0.9	43
164	Apolipoprotein E4 in Parkinson Disease and Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 1998, 12, 45-48.	0.6	43
165	Type 2 Diabetes Mellitus and Impaired Renal Function Are Associated With Brain Alterations and Poststroke Cognitive Decline. <i>Stroke</i> , 2017, 48, 2368-2374.	1.0	43
166	Dementia in the COVID-19 Period. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1071-1072.	1.2	43
167	Naproxen Sodium Versus Ergotamine Tartrate in the Treatment of Acute Migraine Attacks. <i>Headache</i> , 1992, 32, 280-282.	1.8	42
168	The electroencephalogram in acetazolamide-responsive periodic ataxia. <i>Movement Disorders</i> , 1996, 11, 283-288.	2.2	42
169	Disorders of excessive daytime sleepiness—an update. <i>Journal of the Neurological Sciences</i> , 1998, 153, 192-202.	0.3	42
170	The Use of Intravenous Immunoglobulin as Maintenance Therapy in Myasthenia Gravis. <i>Clinical Neuropharmacology</i> , 2001, 24, 173-176.	0.2	42
171	Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). <i>Clinical and Experimental Immunology</i> , 2001, 126, 570-577.	1.1	42
172	Genetic and environmental risk factors for alzheimer's disease in israeli arabs. <i>Journal of Molecular Neuroscience</i> , 2002, 19, 239-245.	1.1	42
173	Increased thrombin inhibition in experimental autoimmune encephalomyelitis. <i>Journal of Neuroscience Research</i> , 2005, 79, 351-359.	1.3	42
174	Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?. <i>Neuroscience Bulletin</i> , 2017, 33, 535-542.	1.5	42
175	Prefrontal Compensatory Mechanism May Enable Normal Semantic Memory Performance in Mild Cognitive Impairment (MCI). <i>Journal of Neuroimaging</i> , 2010, 20, 163-168.	1.0	41
176	Mutation of the nuclear lamin gene <i>LMNB2</i> in progressive myoclonus epilepsy with early ataxia. <i>Human Molecular Genetics</i> , 2015, 24, 4483-4490.	1.4	41
177	The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 876-886.	1.4	41
178	Cerebral amyloid angiopathy impact on endothelium. <i>Experimental Gerontology</i> , 2012, 47, 838-842.	1.2	40
179	Muscle hypertrophy with neuropathy. <i>Journal of the Neurological Sciences</i> , 1978, 38, 399-408.	0.3	39
180	Deficiency of Nicotinic Acetylcholine Receptor $\alpha 24$ Subunit Causes Autonomic Cardiac and Intestinal Dysfunction. <i>Molecular Pharmacology</i> , 2003, 63, 574-580.	1.0	39

#	ARTICLE	IF	CITATIONS
181	The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 243-245.	1.1	39
182	Placebo responses in randomized trials of antiepileptic drugs. <i>Epilepsy and Behavior</i> , 2010, 17, 64-69.	0.9	39
183	Stroke during Sleep: Epidemiological and Clinical Features. <i>Cerebrovascular Diseases</i> , 1999, 9, 320-322.	0.8	38
184	Quantitative anal sphincter EMG in multisystem atrophy and 100 controls. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 71, 596-599.	0.9	38
185	Plasma homocysteine, vitamin B12 and folate in Alzheimer's patients and healthy Arabs in Israel. <i>Journal of the Neurological Sciences</i> , 2004, 227, 109-113.	0.3	38
186	Occurrence of seizures in association with work-related stress in young male army recruits. <i>Epilepsia</i> , 2008, 49, 1451-1456.	2.6	38
187	Why have we Failed to Cure Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 275-282.	1.2	38
188	Cognitive State following Stroke: The Predominant Role of Preexisting White Matter Lesions. <i>PLoS ONE</i> , 2014, 9, e105461.	1.1	38
189	The diagnostic aid of routine EEG findings in patients presenting with a presumed first-ever unprovoked seizure. <i>Epilepsy Research</i> , 2000, 42, 197-202.	0.8	37
190	A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 343-346.	1.3	37
191	Effects of propranolol and pindolol on platelet aggregation and serotonin release. <i>Life Sciences</i> , 1977, 20, 407-411.	2.0	36
192	Parkinsonism in adult-onset GM2 gangliosidosis. <i>Movement Disorders</i> , 1994, 9, 375-377.	2.2	36
193	Should sleep EEG record always be performed after sleep deprivation?. <i>Electroencephalography and Clinical Neurophysiology</i> , 1994, 90, 313-315.	0.3	36
194	The underdiagnosis of the vascular contribution to dementia. <i>Journal of the Neurological Sciences</i> , 2005, 229-230, 3-6.	0.3	36
195	Quality of life in Parkinson's disease: A gender-specific perspective. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 17-22.	1.0	36
196	Apolipoprotein e4 advances appearance of psychosis in patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2006, 113, 14-17.	1.0	35
197	EEG and Topographic Frequency Analysis in Common and Classic Migraine. <i>Headache</i> , 1991, 31, 232-236.	1.8	34
198	Effects of a single intravenous dose of scopolamine on the quantitative EEG in Alzheimer's disease patients and age-matched controls. <i>Electroencephalography and Clinical Neurophysiology</i> , 1994, 91, 407-412.	0.3	34

#	ARTICLE	IF	CITATIONS
199	Hemodynamic effects of liquid food ingestion in mid-thoracic paraplegia: is supine postprandial hypotension related to thoracic spinal cord damage?. <i>Spinal Cord</i> , 2007, 45, 96-103.	0.9	34
200	Progressive Dystonia and Paraparesis in Cerebral Palsy. <i>European Neurology</i> , 1986, 25, 148-153.	0.6	33
201	Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 297-302.	2.2	33
202	High b-value diffusion imaging of dementia: Application to vascular dementia and alzheimer disease. <i>Journal of the Neurological Sciences</i> , 2007, 257, 105-113.	0.3	33
203	Thrombin receptor PAR-1 on myelin at the node of Ranvier: a new anatomy and physiology of conduction block. <i>Brain</i> , 2008, 131, 1113-1122.	3.7	33
204	Neuroprotection in vascular dementia: A future path. <i>Journal of the Neurological Sciences</i> , 2012, 322, 232-236.	0.3	33
205	Vascular and Neurodegenerative Markers for the Prediction of Post-Stroke Cognitive Impairment: Results from the TABASCO Study. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 889-898.	1.2	33
206	Familial levodopa-responsive parkinsonian-pyramidal syndrome. <i>Movement Disorders</i> , 1994, 9, 673-675.	2.2	32
207	Safety profile of copolymer 1: Analysis of cumulative experience in the United States and Israel. <i>Journal of Neurology</i> , 1996, 243, S23-S26.	1.8	32
208	Rotigotine transdermal system for perioperative administration. <i>Journal of Neural Transmission</i> , 2007, 114, 219-221.	1.4	32
209	Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers. <i>Brain</i> , 2009, 132, 2680-2687.	3.7	32
210	Tau and 14-3-3 of genetic and sporadic Creutzfeldtâ€“Jakob disease patients in Israel. <i>Journal of Neurology</i> , 2011, 258, 255-262.	1.8	32
211	Recruitment Rate to Drug Trials for Dementia of the Alzheimer Type. <i>Alzheimer Disease and Associated Disorders</i> , 2000, 14, 209-211.	0.6	31
212	The complex nosological concept of vascular dementia. <i>Journal of the Neurological Sciences</i> , 2002, 203-204, 3-6.	0.3	31
213	Parkin mutation associated parkinsonism and cognitive decline, comparison to early onset Parkinson's disease. <i>Journal of Neural Transmission</i> , 2004, 111, 47-57.	1.4	31
214	Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. <i>Movement Disorders</i> , 2006, 21, 1663-1666.	2.2	31
215	Parkinson's disease: Before the motor symptoms and beyond. <i>Journal of the Neurological Sciences</i> , 2010, 289, 2-6.	0.3	31
216	Dyskinesias in patients with Parkinson's disease: Effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 1039-1041.	1.1	31

#	ARTICLE	IF	CITATIONS
217	High hair cortisol concentrations predict worse cognitive outcome after stroke: Results from the TABASCO prospective cohort study. <i>Psychoneuroendocrinology</i> , 2017, 82, 133-139.	1.3	31
218	Comparison of the Effects of Vigabatrin, Lamotrigine, and Topiramate on Quantitative EEGs in Patients with Epilepsy. <i>Clinical Neuropharmacology</i> , 1999, 22, 80-86.	0.2	30
219	Muscarinic M1 agonists in the treatment of Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2259-2267.	1.9	30
220	Visual evoked potentials in idiopathic intracranial hypertension. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 433-436.	0.6	30
221	Phosphatidylserine Containing Omega-3 Fatty Acids May Improve Memory Abilities in Nondemented Elderly Individuals with Memory Complaints: Results from an Open-Label Extension Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 39-45.	0.7	30
222	A critical review of the prion hypothesis of human synucleinopathies. <i>Cell and Tissue Research</i> , 2018, 373, 213-220.	1.5	30
223	Platelet Aggregability, Disaggregability and Serotonin Uptake in Migraine. <i>Cephalalgia</i> , 1984, 4, 221-225.	1.8	29
224	Does Daily Aspirin Diminish Severity of First-Ever Stroke?. <i>Archives of Neurology</i> , 1997, 54, 1369-1371.	4.9	29
225	Effects of localized pontine lesions on auditory brain-stem evoked potentials and binaural processing in humans. <i>Electroencephalography and Clinical Neurophysiology - Evoked Potentials</i> , 1998, 108, 511-520.	2.0	29
226	Hallucinations in Parkinson's disease. <i>Lancet, The</i> , 2001, 358, 1031-1032.	6.3	29
227	Mental and Motor Switching in Parkinson's Disease. <i>Journal of Motor Behavior</i> , 2001, 33, 377-385.	0.5	29
228	Pruritus in familial Creutzfeldt-Jakob disease: a common symptom associated with central nervous system pathology. <i>Journal of Neurology</i> , 2011, 258, 89-95.	1.8	29
229	Multiple sclerosis and birth order. <i>Acta Neurologica Scandinavica</i> , 1988, 78, 313-317.	1.0	28
230	Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. <i>EPMA Journal</i> , 2010, 1, 273-292.	3.3	28
231	TBC1D24 mutation associated with focal epilepsy, cognitive impairment and a distinctive cerebro-cerebellar malformation. <i>Epilepsy Research</i> , 2013, 105, 240-244.	0.8	28
232	Risk of Dementia after a First-Ever Ischemic Stroke: A 3-Year Longitudinal Study. <i>Cerebrovascular Diseases</i> , 1997, 7, 48-52.	0.8	27
233	Sequential serum creatine kinase determination differentiates vaso-vagal syncope from generalized tonic-clonic seizures. <i>Acta Neurologica Scandinavica</i> , 1997, 95, 137-139.	1.0	27
234	Changes in axonal morphology in experimental autoimmune neuritis as studied by high-value q-space 1H and 2H DQF diffusion magnetic resonance spectroscopy. <i>Magnetic Resonance in Medicine</i> , 2002, 48, 71-81.	1.9	27

#	ARTICLE	IF	CITATIONS
235	Hexosaminidase A deficiency is an uncommon cause of a syndrome mimicking amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2003, 28, 109-112.	1.0	27
236	Generalized convulsive status epilepticus in Creutzfeldtâ€“Jakob disease. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2003, 12, 403-405.	0.9	27
237	Tests of autonomic dysfunction in patients with multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 1995, 92, 356-360.	1.0	27
238	Quantitative measurements of mouse brain thrombin-like and thrombin inhibition activities. <i>NeuroReport</i> , 2001, 12, 2347-2351.	0.6	26
239	Vascular dementia among elderly Arabs in Wadi Ara. <i>Journal of the Neurological Sciences</i> , 2002, 203-204, 73-76.	0.3	26
240	EEG as predictor of dementia following first ischemic stroke. <i>Acta Neurologica Scandinavica</i> , 1994, 90, 263-265.	1.0	26
241	Morphine mydriasis in mice. <i>Life Sciences</i> , 1979, 24, 1667-1673.	2.0	25
242	Patterns of daytime sleepiness in narcoleptics and normals: A pupillometric study. <i>Electroencephalography and Clinical Neurophysiology</i> , 1984, 57, 129-133.	0.3	25
243	Homocysteine, Stroke, and Dementia. <i>Stroke</i> , 2002, 33, 2343-2344.	1.0	25
244	A paradigm for single nucleotide polymorphism analysis: The case of the acetylcholinesterase gene. <i>Human Mutation</i> , 2004, 24, 408-416.	1.1	25
245	CSF tau correlates with CJD disease severity and cognitive decline. <i>Acta Neurologica Scandinavica</i> , 2016, 133, 119-123.	1.0	25
246	Genetic and Environmental Epidemiology of Alzheimer's Disease in Arabs Residing in Israel. <i>Journal of Molecular Neuroscience</i> , 2003, 20, 207-212.	1.1	24
247	Risk factors for Alzheimer's disease in Russia: a caseâ€“control study. <i>European Journal of Neurology</i> , 2006, 13, 990-995.	1.7	24
248	Diaphragmatic involvement in hemiplegia and hemiparesis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1969, 32, 588-590.	0.9	23
249	BELL'S PALSY AND PREGNANCY. <i>Acta Neurologica Scandinavica</i> , 1971, 47, 603-607.	1.0	23
250	Creutzfeldt-Jakob disease among libyan jews. <i>European Journal of Epidemiology</i> , 1991, 7, 490-493.	2.5	23
251	Timing and sequencing of human arm trajectories: Normal and abnormal motor behaviour. <i>Human Movement Science</i> , 1992, 11, 83-100.	0.6	23
252	Topographic distribution of the periodic discharges in Creutzfeldt-Jakob disease (CJD). <i>Brain Topography</i> , 1992, 4, 201-206.	0.8	23

#	ARTICLE	IF	CITATIONS
253	A novel mutation of presenilin 1 in familial Alzheimer's disease in Israel detected by denaturing gradient gel electrophoresis. <i>Human Genetics</i> , 1996, 98, 700-702.	1.8	23
254	Survival in Parkinson's disease: the effect of dementia. <i>Parkinsonism and Related Disorders</i> , 1998, 4, 179-181.	1.1	23
255	Emerging Therapies in the Pharmacological Treatment of Parkinson's Disease. <i>Drugs</i> , 2002, 62, 775-786.	4.9	23
256	Computerized Methods in the Assessment and Prediction of Dementia. <i>Current Alzheimer Research</i> , 2007, 4, 364-369.	0.7	23
257	Biomarkers for Evaluation of Clinical Efficacy of Multipotential Neuroprotective Drugs for Alzheimer's and Parkinson's Diseases. <i>Neurotherapeutics</i> , 2009, 6, 128-140.	2.1	23
258	Multiplex families with epilepsy. <i>Neurology</i> , 2016, 86, 713-722.	1.5	23
259	Convulsive Fits in Thyrotoxicosis. <i>Epilepsia</i> , 1976, 17, 33-34.	2.6	22
260	Spongiform encephalopathy in an Israeli born to immigrants from Libya. <i>Lancet, The</i> , 1990, 336, 686.	6.3	22
261	Familial Alzheimer's disease associated with S182 codon 286 mutation. <i>Lancet, The</i> , 1995, 346, 1040.	6.3	22
262	Dihydroergotamine Nasal Spray in the Treatment of Acute Migraine. <i>Headache</i> , 1998, 38, 614-617.	1.8	22
263	Zolmitriptan Provides Consistent Migraine Relief when Used in the Long Term. <i>Current Medical Research and Opinion</i> , 1999, 15, 272-281.	0.9	22
264	Founder Effect with Variable Age at Onset in Arab Families with Lafora Disease and EPM2A Mutation. <i>Epilepsia</i> , 2007, 48, 1011-1014.	2.6	22
265	Mild adolescent/adult onset epilepsy and paroxysmal exercise-induced dyskinesia due to GLUT1 deficiency. <i>Epilepsia</i> , 2010, 51, 2466-2469.	2.6	22
266	Cerebral White Matter Disruption in Creutzfeldt-Jakob Disease. <i>American Journal of Neuroradiology</i> , 2012, 33, 1945-1950.	1.2	22
267	Drug treatment of Parkinson's disease. <i>Dialogues in Clinical Neuroscience</i> , 2004, 6, 315-322.	1.8	22
268	Lateralization and binaural discrimination of patients with pontine lesions. <i>Journal of the Acoustical Society of America</i> , 1998, 103, 2624-2633.	0.5	21
269	Denbufylline in Dementia: A Double-Blind Controlled Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 505-510.	0.7	21
270	Demented patients' participation in a clinical trial: factors affecting the caregivers' decision. , 2000, 15, 325-330.		21

#	ARTICLE	IF	CITATIONS
271	Epidemiology of dementia in Ashkelon. <i>Journal of Neurology</i> , 2003, 250, 424-428.	1.8	21
272	Human-computer interaction in the administration and analysis of neuropsychological tests. <i>Computer Methods and Programs in Biomedicine</i> , 2004, 73, 43-53.	2.6	21
273	Management of sleep problems in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 248, 163-166.	0.3	21
274	Autonomic impairment in a transgenic mouse model of amyotrophic lateral sclerosis. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2011, 159, 84-89.	1.4	21
275	Occurrence of fatigue over 20 years after recovery from Guillain-Barré syndrome. <i>Journal of the Neurological Sciences</i> , 2012, 316, 72-75.	0.3	21
276	Gait Measures as Predictors of Poststroke Cognitive Function. <i>Stroke</i> , 2015, 46, 1077-1083.	1.0	21
277	Transient Bilateral Diaphragmatic Paralysis. <i>Chest</i> , 1973, 64, 355-357.	0.4	20
278	Unverricht-Lundborg disease in a five-generation Arab family. <i>Neurology</i> , 2001, 57, 1050-1054.	1.5	20
279	Inhibition of Ras attenuates the course of experimental autoimmune neuritis. <i>Journal of Neuroimmunology</i> , 2005, 168, 46-55.	1.1	20
280	Commentary on "Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." <i>Alzheimer's and Dementia</i> , 2011, 7, 333-334.	0.4	20
281	The Role of Sex Therapy in the Management of Patients with Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 6-13.	0.8	20
282	EEG in Cerebrotendinous Xanthomatosis (CTX). <i>Clinical EEG (electroencephalography)</i> , 1982, 13, 89-96.	0.9	19
283	A Mutation in the Prion Protein Gene in Creutzfeldt-Jakob Disease in Jewish Patients of Libyan, Greek, and Tunisian Origin. <i>Annals of the New York Academy of Sciences</i> , 1991, 640, 171-176.	1.8	19
284	Transient musical hallucinosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993, 56, 833-833.	0.9	19
285	Persistent hemiballism in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994, 57, 1013-1014.	0.9	19
286	Electroencephalographic Findings with Low-Dose Clozapine Treatment in Psychotic Parkinsonian Patients. <i>Clinical Neuropharmacology</i> , 1996, 19, 81-86.	0.2	19
287	Letters to the editor. <i>Movement Disorders</i> , 1996, 11, 115-116.	2.2	19
288	Postmeningitis Headache. <i>Headache</i> , 1999, 39, 132-134.	1.8	19

#	ARTICLE	IF	CITATIONS
289	Cerebral vasomotor reactivity in Parkinson's disease, multiple system atrophy and pure autonomic failure. <i>Journal of the Neurological Sciences</i> , 2006, 243, 57-60.	0.3	19
290	Epilepsy, behavior, and art (Epilepsy, Brain, and Mind, part 1). <i>Epilepsy and Behavior</i> , 2013, 28, 261-282.	0.9	19
291	Sodium channel localization in rat sciatic nerve following lead-induced demyelination. <i>Brain Research</i> , 1985, 359, 326-331.	1.1	18
292	Painful calf, moving foot. <i>Movement Disorders</i> , 1996, 11, 339-340.	2.2	18
293	Prevalence of myotonic dystrophy in Israeli Jewish communities: Inter-community variation and founder premutations. <i>American Journal of Medical Genetics Part A</i> , 2003, 119A, 273-278.	2.4	18
294	Willingness to Use Computerized Systems for the Diagnosis of Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 171-178.	0.6	18
295	Familial Creutzfeldtâ€“Jakob disease with the E200K mutation: longitudinal neuroimaging from asymptomatic to symptomatic CJD. <i>Journal of Neurology</i> , 2015, 262, 604-613.	1.8	18
296	The pathophysiology of dystonia. <i>Journal of Neural Transmission</i> , 1978, 42, 245-250.	1.4	17
297	Muscarinic acetylcholine receptors in cat iris. <i>Biochemical Pharmacology</i> , 1979, 28, 1505-1511.	2.0	17
298	Abolition of oxotremorine effects by l-DOPA pretreatment. <i>Neuropharmacology</i> , 1979, 18, 601-603.	2.0	17
299	The ocular effects of cannabinoids. <i>General Pharmacology</i> , 1980, 11, 419-423.	0.7	17
300	Pruritus in Creutzfeldt-Jakob disease. <i>Neurology</i> , 1996, 46, 940-941.	1.5	17
301	Esophageal smooth muscle dysfunction in oculopharyngeal muscular dystrophy. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1350-1354.	1.1	17
302	Assessment of experimental autoimmune neuritis in the rat by electrophysiology of the tail nerve. <i>Muscle and Nerve</i> , 2002, 25, 51-57.	1.0	17
303	Modified Cold Pressor Test by Cold Application to the Foot After Spinal Cord Injury. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2007, 86, 875-882.	0.7	17
304	Computerized diagnosis of mild cognitive impairment. , 2007, 3, 23-27.		17
305	Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. <i>Neurobiology of Aging</i> , 2011, 32, 272-279.	1.5	17
306	Cognitive state following mild stroke: A matter of hippocampal mean diffusivity. <i>Hippocampus</i> , 2016, 26, 161-169.	0.9	17

#	ARTICLE	IF	CITATIONS
307	Quality-of-life perception by Parkinson's disease patients and caregivers. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 151-154.	1.0	17
308	The Price of Stress: High Bedtime Salivary Cortisol Levels Are Associated with Brain Atrophy and Cognitive Decline in Stroke Survivors. Results from the TABASCO Prospective Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1365-1375.	1.2	17
309	Computed tomography brain changes in Parkinsonian dementia. <i>Neuroradiology</i> , 1987, 29, 535-539.	1.1	16
310	Carbamazepine-Induced Systemic Lupus Erythematosus. <i>Clinical Neuropharmacology</i> , 1989, 12, 115-118.	0.2	16
311	Effects of Atropine on Learning and Memory Functions in Dementia. <i>Clinical Neuropharmacology</i> , 1990, 13, 241-247.	0.2	16
312	Genetic and Environmental Factors Determining the Development of Creutzfeldt-Jakob Disease in Libyan Jews. <i>Neuroepidemiology</i> , 1991, 10, 228-231.	1.1	16
313	Parkinson's and Alzheimer's Diseases: Epidemiological Comparison. <i>Neuroepidemiology</i> , 1993, 12, 336-344.	1.1	16
314	Beneficial Effect of Cabergoline, New Long-Lasting D2 Agonist in the Treatment of Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1994, 17, 286-293.	0.2	16
315	Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease. <i>Movement Disorders</i> , 1995, 10, 604-607.	2.2	16
316	An open trial of amantadine and buspirone for cerebellar ataxia: a disappointment. <i>Journal of Neural Transmission</i> , 2000, 107, 1187-1189.	1.4	16
317	The assessment of radiating low back pain by thermal sensory testing. <i>European Journal of Pain</i> , 2001, 5, 347-351.	1.4	16
318	R-R interval variation in Parkinson's disease and multiple system atrophy. <i>Acta Neurologica Scandinavica</i> , 2004, 109, 276-279.	1.0	16
319	Analysis of Genetic Polymorphisms in Acetylcholinesterase as Reflected in Different Populations. <i>Current Alzheimer Research</i> , 2005, 2, 207-218.	0.7	16
320	Cold pressor test in tetraplegia and paraplegia suggests an independent role of the thoracic spinal cord in the hemodynamic responses to cold. <i>Spinal Cord</i> , 2008, 46, 33-38.	0.9	16
321	The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. <i>Acta Neurologica Scandinavica</i> , 2011, 123, 117-121.	1.0	16
322	Seizures as presenting and prominent symptom in chorea-acanthocytosis with c.2343del <sc>VPS</sc>13A</i> gene mutation. <i>Epilepsia</i> , 2016, 57, 549-556.	2.6	16
323	Apolipoprotein E and Parkinson's disease. <i>Annals of Neurology</i> , 1998, 44, 294-294.	2.8	15
324	Dosing with ropinirole in a clinical setting. <i>Acta Neurologica Scandinavica</i> , 2002, 106, 200-204.	1.0	15

#	ARTICLE	IF	CITATIONS
325	Cerebral vasomotor reactivity of patients with acute ischemic stroke: Cortical versus subcortical infarcts: An Israeli-Turkish collaborative study. <i>Journal of the Neurological Sciences</i> , 2007, 257, 121-125.	0.3	15
326	Can the disease course in Parkinson's disease be slowed?. <i>BMC Medicine</i> , 2015, 13, 295.	2.3	15
327	Depressive Symptoms Following Stroke and Transient Ischemic Attack. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 673-680.	1.1	15
328	Dopaminergic and non-dopaminergic circling activity of mice. <i>Neuroscience</i> , 1979, 4, 1085-1088.	1.1	14
329	Decreased (3H) quinuclidinyl benzilate binding to lymphocytes in Gilles de la Tourette syndrome. <i>Biological Psychiatry</i> , 1992, 31, 889-895.	0.7	14
330	The sympathetic skin response in reflex sympathetic dystrophy. <i>Journal of the Neurological Sciences</i> , 1995, 128, 92-95.	0.3	14
331	Intermittent rhythmic delta activity (IRDA) morphology cannot distinguish between focal and diffuse brain disturbances. <i>Journal of the Neurological Sciences</i> , 1999, 164, 56-59.	0.3	14
332	Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine. <i>Journal of Anesthesia</i> , 2001, 15, 204-209.	0.7	14
333	Antiphospholipid Antibodies Bind ATP: A putative Mechanism for the Pathogenesis of Neuronal Dysfunction. <i>Clinical and Developmental Immunology</i> , 2005, 12, 175-180.	3.3	14
334	Seizures of unknown origin after the age of 50: vascular risk factors. <i>Acta Neurologica Scandinavica</i> , 1990, 82, 78-80.	1.0	14
335	The Creutzfeldt-Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 368-374.	1.0	14
336	Mild cognitive impairment in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2013, 120, 517-521.	1.4	14
337	Cognitive Assessment in Proximity to Acute Ischemic Stroke/Transient Ischemic Attack: Comparison of the Montreal Cognitive Assessment Test and MindStreams Computerized Cognitive Assessment Battery. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 36, 36-42.	0.7	14
338	Neuroprotection in ischemic stroke: what does the future hold?. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 227-229.	1.4	14
339	Unusual presentations in patients with E200K familial Creutzfeldt-Jakob disease. <i>European Journal of Neurology</i> , 2016, 23, 871-877.	1.7	14
340	Central and peripheral components of morphine mydriasis in mice. <i>Pharmacology Biochemistry and Behavior</i> , 1982, 17, 897-899.	1.3	13
341	DSM-III Criteria for Primary Degenerative Dementia and Multi-Infarct Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 1992, 6, 111-118.	0.6	13
342	Intravascular Malignant Lymphomatosis: A Cause of Subacute Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 1995, 6, 286-293.	0.7	13

#	ARTICLE	IF	CITATIONS
343	Changes in expression of lymphocyte amyloid precursor protein mRNA isoforms in normal aging and Alzheimer's disease. <i>Molecular Brain Research</i> , 1996, 35, 260-268.	2.5	13
344	N30 somatosensory evoked potentials in patients with unilateral Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 1998, 97, 73-76.	1.0	13
345	Immunohistochemical analysis of sympathetic involvement in the SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 424-433.	1.1	13
346	Third International Congress on Epilepsy, Brain and Mind: Part 1. <i>Epilepsy and Behavior</i> , 2015, 50, 116-137.	0.9	13
347	Physically traumatic events in patients with epilepsy compared with non-epileptic subjects. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2000, 9, 595-597.	0.9	12
348	Is amnesic mild cognitive impairment a useful concept?. <i>Aging Health</i> , 2011, 7, 107-122.	0.3	12
349	Parkinson's disease: one disease entity or many?. <i>Journal of Neural Transmission Supplementum</i> , 1999, 56, 107-111.	0.5	12
350	Waardenburg syndrome with a fixed dilated pupil.. <i>British Journal of Ophthalmology</i> , 1978, 62, 491-494.	2.1	11
351	Antibodies to muscarinic acetylcholine receptors in myasthenia gravis. <i>Biochemical and Biophysical Research Communications</i> , 1982, 104, 52-57.	1.0	11
352	Magnetic resonance imaging (MRI) in patients with complex partial seizures and normal computerized tomography (CT) scan. <i>Clinical Neurology and Neurosurgery</i> , 1987, 89, 231-235.	0.6	11
353	Cerebrovascular symptoms in thromboangiitis obliterans. <i>Acta Neurologica Scandinavica</i> , 1989, 80, 347-350.	1.0	11
354	Cognitive effects of scopolamine in dementia. <i>Journal of Neural Transmission</i> , 1996, 103, 873-881.	1.4	11
355	Copolymer 1 (Glatiramer Acetate) in Relapsing Forms of Multiple Sclerosis: Open Multicenter Study of Alternate-Day Administration. <i>Clinical Neuropharmacology</i> , 2002, 25, 11-15.	0.2	11
356	Hamilton Depression Scale in dementia. <i>International Journal of Psychiatry in Clinical Practice</i> , 2002, 6, 91-94.	1.2	11
357	Subdivision of essential tremor patients according to physiologic characteristics. <i>Acta Neurologica Scandinavica</i> , 2004, 109, 393-397.	1.0	11
358	Increased KPI containing amyloid precursor protein in experimental autoimmune encephalomyelitis brains. <i>NeuroReport</i> , 2007, 18, 581-584.	0.6	11
359	Identification of Histidine-Rich Glycoprotein, a Potential Autoantigen, in Human and Rat Brain Preparations. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 473-483.	1.8	11
360	Can Treatment With Nonsteroidal Anti-inflammatory Drugs Protect From Dementia?. <i>Archives of Neurology</i> , 2009, 66, 538.	4.9	11

#	ARTICLE	IF	CITATIONS
361	Lay persons' beliefs and knowledge about Parkinson's disease: Prevalence and socio-demographic correlates. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 415-417.	1.1	11
362	Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension. <i>BMC Neurology</i> , 2011, 11, 79.	0.8	11
363	Acquired Oculomotor Nerve Paresis with Cyclic Spasms in a Young Woman, a Rare Subtype of Neuromyotonia. <i>Journal of Neuro-Ophthalmology</i> , 2013, 33, 247-248.	0.4	11
364	Effect of brain stem transections on vasomotor responses to nerve stimulation. <i>Archives Internationales De Physiologie Et De Biochimie</i> , 1963, 71, 662-673.	0.2	10
365	The mechanism of imipramine in enuresis nocturna. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1979, 6, 31-35.	0.9	10
366	The effect of dopamine on the pupillary diameter in mice. <i>Life Sciences</i> , 1980, 26, 757-763.	2.0	10
367	The Clinical Differential Diagnosis of Dementia: Concept and Methodology. <i>Psychiatric Clinics of North America</i> , 1991, 14, 237-249.	0.7	10
368	Neurologic genetic diseases of Jewish people. <i>Biomedicine and Pharmacotherapy</i> , 1994, 48, 391-397.	2.5	10
369	Phenotypic heterogeneity in familial inclusion body myopathy. <i>Muscle and Nerve</i> , 1995, 18, 546-548.	1.0	10
370	Prion diseases. <i>Current Opinion in Neurology</i> , 1997, 10, 273.	1.8	10
371	Germline mutational analysis of presenilin 1 and APP genes in Jewish-Israeli individuals with familial or early-onset Alzheimer disease using denaturing gradient gel electrophoresis (DGGE). <i>European Journal of Human Genetics</i> , 1998, 6, 176-180.	1.4	10
372	Nicotinic acetylcholine receptor $\alpha 5$ subunits modulate oxotremorine-induced salivation and tremor. <i>Journal of the Neurological Sciences</i> , 2004, 222, 87-91.	0.3	10
373	Dementia with Lewy bodies. <i>Journal of the Neurological Sciences</i> , 2006, 248, 3-8.	0.3	10
374	Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 525-528.	0.5	10
375	Vascular Contribution to Dementia in Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 127-130.	0.8	10
376	Hemodynamic responses to head-up tilt after spinal cord injury support a role for the mid-thoracic spinal cord in cardiovascular regulation. <i>Spinal Cord</i> , 2011, 49, 251-256.	0.9	10
377	Benign Neonatal Sleep Myoclonus. <i>Journal of Child Neurology</i> , 2012, 27, 1260-1263.	0.7	10
378	Parkinson's and Alzheimer's diseases: Focus on mild cognitive impairment. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S159-S161.	1.1	10

#	ARTICLE	IF	CITATIONS
379	Correlation of Headache Complaints With Some Physiological Parameters in a Healthy Population. <i>Headache</i> , 1980, 20, 196-198.	1.8	9
380	Enkephalin mydriasis in mice. <i>European Journal of Pharmacology</i> , 1980, 65, 285-287.	1.7	9
381	Effect of Pilocarpine on Intraocular Pressure in Ocular Hypertensive Subjects. <i>Ophthalmic Research</i> , 1986, 18, 34-37.	1.0	9
382	Encephalopathy Associated with Sulindac. <i>Human Toxicology</i> , 1986, 5, 55-55.	0.9	9
383	Laterality of onset in idiopathic torsion dystonia. <i>Movement Disorders</i> , 1993, 8, 327-330.	2.2	9
384	Interrater agreement in evaluation of stroke patients with the unified neurological stroke scale.. <i>Stroke</i> , 1994, 25, 1263-1264.	1.0	9
385	Vascular parkinsonism. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 417-425.	1.0	9
386	Insulin resistance in tetraplegia but not in mid-thoracic paraplegia: is the mid-thoracic spinal cord involved in glucose regulation?. <i>Spinal Cord</i> , 2011, 49, 648-652.	0.9	9
387	Modeling the Dementia Epidemic. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 175-181.	1.9	9
388	Characterization of sleep disorders in patients with E200K familial Creutzfeldtâ€“Jakob disease. <i>Journal of Neurology</i> , 2015, 262, 443-450.	1.8	9
389	Disease duration in E200K familial Creutzfeldtâ€“Jakob disease is correlated with clinical, radiological, and laboratory variables. <i>Journal of Neural Transmission</i> , 2019, 126, 607-611.	1.4	9
390	Is dementia preventable?. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 213-216.	1.8	9
391	Asymmetry of turning behaviour of rats induced by amphetamine and apomorphine. <i>Experientia</i> , 1978, 34, 616-616.	1.2	8
392	Amantadine antagonism of oxotremorine effects. <i>Journal of Neural Transmission</i> , 1979, 46, 79-83.	1.4	8
393	Amethocaine and Intraocular Pressure. <i>Ophthalmic Research</i> , 1979, 11, 212-215.	1.0	8
394	Lingual Seizures ¹ . <i>Epilepsia</i> , 1988, 29, 30-33.	2.6	8
395	Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome. <i>Immunobiology</i> , 2003, 207, 47-50.	0.8	8
396	Hidden function of neuronal nicotinic acetylcholine receptor $\alpha 2$ subunits in ganglionic transmission: comparison to $\alpha 5$ and $\alpha 4$ subunits. <i>Journal of the Neurological Sciences</i> , 2005, 228, 167-177.	0.3	8

#	ARTICLE	IF	CITATIONS
397	Visual disturbances in Parkinson's disease. <i>Practical Neurology</i> , 2006, 6, 28-33.	0.5	8
398	Blood pressure measurements in a transgenic SOD1-G93A mouse model of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2012, 13, 509-513.	2.3	8
399	Vasomotor reactivity as a predictor for syncope in patients with orthostatism. <i>Acta Neurologica Scandinavica</i> , 2012, 126, 32-36.	1.0	8
400	Third International Congress on Epilepsy, Brain, and Mind: Part 2. <i>Epilepsy and Behavior</i> , 2015, 50, 138-159.	0.9	8
401	Familial Creutzfeldtâ€“Jakob disease homozygous to the E200K mutation: clinical characteristics and disease course. <i>Journal of Neurology</i> , 2020, 267, 2455-2458.	1.8	8
402	Treating Tardive Dyskinesia With Ondansetron. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 355-356.	0.7	8
403	Dopaminergic drugs in development for Parkinson's disease. <i>Advances in Neurology</i> , 2003, 91, 267-71.	0.8	8
404	The stability of dopamine-âˆ²-hydroxylase activity in blood samples. <i>Clinica Chimica Acta</i> , 1978, 82, 291-292.	0.5	7
405	Tolerance to the mydriatic effects of morphine in mice. <i>Journal of Neural Transmission</i> , 1980, 48, 43-47.	1.4	7
406	ANTAGONISM OF OPIATE MYDRIASIS IN MICE. <i>British Journal of Pharmacology</i> , 1981, 73, 807-810.	2.7	7
407	Denervation supersensitivity in the canine heart: Catecholamine-enhanced positive chronotropy without altered arrhythmogenicity. <i>American Heart Journal</i> , 1982, 103, 443-445.	1.2	7
408	Natural Course of Idiopathic Torsion Dystonia among Jews. <i>Neuroepidemiology</i> , 1994, 13, 195-201.	1.1	7
409	Decreased dopamine uptake into platelet storage granules in Gilles de la Tourette disease. <i>Biological Psychiatry</i> , 1995, 38, 112-115.	0.7	7
410	Cerebral atherosclerosis in Parkinsonian patients. <i>Parkinsonism and Related Disorders</i> , 1998, 4, 87-90.	1.1	7
411	Quality of life in Alzheimer's disease. <i>European Journal of Neurology</i> , 1999, 6, 487-489.	1.7	7
412	Pure congenital Foixâ€“Chavanyâ€“Marie syndrome. <i>Developmental Medicine and Child Neurology</i> , 1997, 39, 696-698.	1.1	7
413	Cerebral vasomotor reactivity and dementia after ischemic stroke. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 383-388.	1.0	7
414	Is vascular cognitive impairment a useful concept?. <i>Journal of the Neurological Sciences</i> , 2010, 299, 2-4.	0.3	7

#	ARTICLE	IF	CITATIONS
415	A Practical Measurement of Parkinson's Patients Gait Using Simple Walker-Based Motion Sensing and Data Analysis. <i>Journal of Medical Devices, Transactions of the ASME</i> , 2018, 12, .	0.4	7
416	Clinical and radiological determinants of transient symptoms associated with infarction (TSI). <i>Journal of the Neurological Sciences</i> , 2018, 390, 195-199.	0.3	7
417	Posttraumatic Stress Symptoms After Stroke: The Effects of Anatomy and Coping Style. <i>Stroke</i> , 2022, 53, 1924-1933.	1.0	7
418	Denervation Supersensitivity in Horner's Syndrome. <i>Ophthalmologica</i> , 1975, 170, 313-319.	1.0	6
419	Circadian Rhythm of the Pupillary Response to Morphine and to Naloxone. <i>Chronobiology International</i> , 1985, 2, 239-241.	0.9	6
420	Dopaminergic drugs influence the intensity of catalepsy induced by microinjections of carbachol into the reticular formation. <i>Neuroscience Letters</i> , 1990, 119, 245-248.	1.0	6
421	The Lupus Anticoagulant and Dementia in Non-SLE Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 1992, 3, 140-145.	0.7	6
422	Neuroanatomical Aspects of Mydriatic Action of Morphine in Rats. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 1997, 13, 405-413.	0.6	6
423	Late-life depression as a risk factor for dementia. <i>Future Neurology</i> , 2007, 2, 201-208.	0.9	6
424	Drugs for vascular dementia. <i>Lancet Neurology</i> , The, 2007, 6, 749-751.	4.9	6
425	Is Alzheimer's disease a homogeneous disease entity?. <i>Journal of Neural Transmission</i> , 2013, 120, 1475-1477.	1.4	6
426	What is new in vascular dementia?. <i>BMC Medicine</i> , 2016, 14, 175.	2.3	6
427	Gait instability in valproate-treated patients: Call to measure ammonia levels. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 401-406.	1.0	6
428	Heparin in the Treatment of Acute Stroke. <i>Neurologic Clinics</i> , 1992, 10, 209-217.	0.8	6
429	Re: The Apolipoprotein E ϵ 4 Allele Increases the Risk of Drug-Induced Hallucinations in Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2000, 23, 230-231.	0.2	6
430	Characterization of movement disorders in patients with familial Creutzfeldt-Jakob disease carrying the E200K mutation. <i>Israel Medical Association Journal</i> , 2012, 14, 162-5.	0.1	6
431	The Lived Experience of Parkinson's Disease: A Content Analysis of Parkinson's Patients' Blogs. <i>Israel Medical Association Journal</i> , 2017, 19, 685-690.	0.1	6
432	Electroretinographic responses in lafora disease. <i>Electroencephalography and Clinical Neurophysiology</i> , 1978, 45, 785-788.	0.3	5

#	ARTICLE	IF	CITATIONS
433	Lack of effect of cannabinoids on carbonic anhydrase. <i>Journal of Neural Transmission</i> , 1980, 49, 205-206.	1.4	5
434	The effect of L-dopa on pupillary diameter in mice. <i>Experientia</i> , 1982, 38, 481-482.	1.2	5
435	Cardiac denervation supersensitivity produced in guinea pigs by 6-hydroxy-dopamine. <i>Pharmacological Research Communications</i> , 1984, 16, 171-179.	0.2	5
436	Ocular Tension: Comparison between the Two Eyes. <i>Ophthalmologica</i> , 1985, 190, 98-101.	1.0	5
437	Increased platelet aggregation and release reaction in myotonic dystrophy. <i>Journal of the Neurological Sciences</i> , 1988, 84, 239-246.	0.3	5
438	Sympathomimetic amines and cardiac arrhythmias. <i>Cardiovascular Research</i> , 1990, 24, 754-757.	1.8	5
439	Rats immunized with cholinergic synaptosomes: A model for Lambert-Eaton syndrome. <i>Muscle and Nerve</i> , 1990, 13, 726-733.	1.0	5
440	Carpal tunnel syndrome: A complication of idiopathic torsion dystonia. <i>Movement Disorders</i> , 1991, 6, 82-84.	2.2	5
441	Action of opioid agonist-antagonist drugs on the pupil and nociceptive responses in mice. <i>Journal of Anesthesia</i> , 1992, 6, 439-445.	0.7	5
442	Alzheimer's disease and vascular brain lesions. <i>Journal of the Neurological Sciences</i> , 2005, 231, 1-2.	0.3	5
443	Transdermal therapy in Parkinson's disease. <i>Lancet Neurology</i> , The, 2007, 6, 475-476.	4.9	5
444	Comment: should we diagnose MCI in Parkinson disease?. <i>Journal of Neural Transmission</i> , 2011, 118, 1177-1177.	1.4	5
445	Can the RAVLT predict deterioration from MCI to dementia? Data from long term follow up. <i>Experimental Aging Research</i> , 2021, 47, 347-356.	0.6	5
446	Sexuality and Parkinson's Disease. , 0, , 517-526.		5
447	Central connections of the salivation reflex in man. <i>Experimental Neurology</i> , 1978, 62, 497-499.	2.0	4
448	Dopamine- β -hydroxylase (DBH) in idiopathic torsion dystonia (ITD). <i>Journal of the Neurological Sciences</i> , 1982, 53, 91-93.	0.3	4
449	Pain and hyperpathia in pontine haemorrhage. <i>Journal of Neurology</i> , 1983, 230, 205-208.	1.8	4
450	Somatostatin mydriasis in mice. <i>Life Sciences</i> , 1983, 32, 1053-1056.	2.0	4

#	ARTICLE	IF	CITATIONS
451	Non-Migrainous Headache and Transient Neurological Deficits. <i>Headache</i> , 1985, 25, 271-272.	1.8	4
452	Serial EEG Recordings following Intrathecal Metrizamide Administration. <i>Clinical EEG (electroencephalography)</i> , 1989, 20, 202-208.	0.9	4
453	APOE ϵ 4 in age-related memory complaints and Alzheimer's disease. <i>European Journal of Neurology</i> , 1996, 3, 515-518.	1.7	4
454	Autonomic dysfunction in experimental autoimmune neuritis. <i>Journal of the Neurological Sciences</i> , 2001, 184, 183-188.	0.3	4
455	Recruitment for Drug Studies in Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2002, 16, 283-284.	0.6	4
456	Drug Trials in Dementia: Challenging Ethical Dilemmas. <i>Current Alzheimer Research</i> , 2007, 4, 468-472.	0.7	4
457	Preface to special issue on Mental Dysfunction in Parkinson's Disease. <i>Journal of the Neurological Sciences</i> , 2010, 289, 1.	0.3	4
458	Nonarteritic Ischemic Optic Neuropathy and Other Vascular Diseases. <i>Neuroepidemiology</i> , 2013, 40, 225-226.	1.1	4
459	CSF tau correlates with the degree of cortical involvement in E200K familial Creutzfeldt-Jakob disease. <i>Neuroscience Letters</i> , 2016, 634, 76-78.	1.0	4
460	Medical Cannabis for Gilles de la Tourette Syndrome: An Open-Label Prospective Study. <i>Behavioural Neurology</i> , 2022, 2022, 1-10.	1.1	4
461	Effect of brain transections on the respiratory response to nerve stimulation. <i>Journal of the Neurological Sciences</i> , 1965, 2, 241-252.	0.3	3
462	Respiratory responses to brain stem stimulation. <i>Journal of the Neurological Sciences</i> , 1966, 3, 217-228.	0.3	3
463	Serum Dopamine Beta-Hydroxylase Activity in Acute Cardiac Disease. <i>Chest</i> , 1978, 74, 522-525.	0.4	3
464	Effect of Pilocarpine on Intraocular Pressure in Normal Humans. <i>Ophthalmic Research</i> , 1982, 14, 182-187.	1.0	3
465	Antineurofilament antibodies in postpolio syndrome. <i>Neurology</i> , 1998, 51, 1193-1195.	1.5	3
466	Penetrance and Phenotypic Expression of a Mutation Linked to Creutzfeldt-Jakob Disease in the Elderly. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 47-50.	0.7	3
467	Precipitation of Hereditary Motor-Sensory Neuropathy Following Hepatitis B Vaccination. <i>Journal of Clinical Neuromuscular Disease</i> , 2001, 3, 75-76.	0.3	3
468	Dementia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 248, 1-2.	0.3	3

#	ARTICLE	IF	CITATIONS
469	Comments on the article by Mazza <i>et al.</i> concerning <i>Ginkgo biloba</i> and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. <i>European Journal of Neurology</i> , 2007, 14, e9; author reply e10.	1.7	3
470	Possible remote functional reorganization in left temporal lobe epilepsy. <i>Acta Neurologica Scandinavica</i> , 2008, 117, 324-331.	1.0	3
471	Is there a need to redefine Parkinson's disease?. <i>Journal of the Neurological Sciences</i> , 2011, 310, 2-3.	0.3	3
472	The effect of schooling on reported age of onset of cognitive decline: A collaborative study. <i>Journal of Clinical Neuroscience</i> , 2016, 34, 86-88.	0.8	3
473	Clinical radiological correlation in E200K familial Creutzfeldt-Jakob disease. <i>Journal of Neural Transmission</i> , 2016, 123, 1457-1462.	1.4	3
474	Creutzfeldt-Jakob and Vascular Brain Diseases: Their Overlap and Relationships. <i>Frontiers in Neurology</i> , 2021, 12, 613991.	1.1	3
475	The assessment of cognitive and behavioural disturbances in vascular cognitive impairment (VCI) – recommendations of an expert working group. <i>Neurologia i Neurochirurgia Polska</i> , 2021, 55, 333-345.	0.6	3
476	Effect of electroconvulsive treatment on serum dopamine-beta-hydroxylase activity in man. <i>Experientia</i> , 1978, 34, 212-213.	1.2	2
477	Rostaglandins Do Not Affect Ion Concentrations in Human Erythrocytes. <i>Archives Internationales De Physiologie Et De Biochimie</i> , 1979, 87, 311-314.	0.2	2
478	Effect of β -Blockers on Sodium and Potassium Content of Human Erythrocytes. <i>Archives Internationales De Physiologie Et De Biochimie</i> , 1979, 87, 935-941.	0.2	2
479	Dopamine-beta-hydroxylase activity in serum of patients with hepatic damage. <i>Progress in Neuro-Psychopharmacology & Biological Psychiatry</i> , 1979, 3, 551-553.	0.6	2
480	The Specificity of the Pupillary Actions of Morphine and Naloxone. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 1987, 3, 17-21.	0.6	2
481	Nicotine mydriasis. <i>Drug and Alcohol Dependence</i> , 1989, 23, 133-136.	1.6	2
482	EEG Recordings Following Intrathecal Iohexol Administration. <i>Clinical Neuropharmacology</i> , 1990, 13, 318-321.	0.2	2
483	High blood pressure and dementia. <i>Lancet</i> , The, 1996, 348, 65.	6.3	2
484	A statistical method for quantitative evaluation of the progression of chronic diseases: the mean score graph (MSG). , 1998, 17, 2395-2403.		2
485	5-hydroxytryptamine in platelets of torsion dystonia patients. <i>Acta Neurologica Scandinavica</i> , 2009, 71, 171-173.	1.0	2
486	Vascular dementia 2007. <i>Journal of the Neurological Sciences</i> , 2009, 283, 1.	0.3	2

#	ARTICLE	IF	CITATIONS
487	Delayed Start, Rapid Solution?. Neuroepidemiology, 2010, 35, 214-214.	1.1	2
488	Preface. Journal of the Neurological Sciences, 2011, 310, 1.	0.3	2
489	Asymptomatic carotid artery stenosis (ACAS). Journal of Neural Transmission, 2011, 118, 629-629.	1.4	2
490	43 Why have we failed to cure Alzheimer's disease?. Neurobiology of Aging, 2012, 33, S19.	1.5	2
491	Elevated titers of anti-thyroperoxidase antibodies in patients with multiple system atrophy: A pilot study. Clinical Neurology and Neurosurgery, 2013, 115, 2348-2350.	0.6	2
492	Life Style and the Prevention of Dementia. Neuroepidemiology, 2015, 44, 83-84.	1.1	2
493	Atypical duration of epileptic and psychogenic nonepileptic events. Epilepsy and Behavior, 2020, 111, 107145.	0.9	2
494	Gastric Dysfunction in Parkinson's Disease. , 2013, , 145-154.		2
495	The Use of Biomarkers for Prediction and Prevention of Alzheimer's and Parkinson's Diseases. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 95-140.	0.6	2
496	Computerized Methods for Cognitive Testing. , 2008, , 203-215.		2
497	Surveying Global Availability of Parkinson's Disease Treatment. Journal of Parkinson's Disease, 2022, 12, 1023-1034.	1.5	2
498	THE VESTIBULO-OCULAR REFLEX AND DYSEQUILIBRIUM AFTER HEMISPHERIC STROKE1. American Journal of Physical Medicine and Rehabilitation, 1994, 73, 36-39.	0.7	2
499	Phenytoin and folate deficiency: Failure to show dose dependency. Journal of Neurology, 1974, 207, 151-153.	1.8	1
500	Cholesterol and uric acid levels in patients with bell's palsy. Journal of Neurology, 1975, 208, 315-317.	1.8	1
501	Ventilatory response to carbon dioxide in multiple sclerosis. Journal of Neurology, 1977, 215, 67-71.	1.8	1
502	The function of presynaptic dopamine receptors on noradrenergic nerve terminals. Medical Hypotheses, 1979, 5, 1131-1132.	0.8	1
503	SERUM DOPAMINE ?-HYDROXYLASE (D?H) LEVELS DURING TILTING IN PATIENTS WITH SPINAL CORD INJURIES. Clinical and Experimental Pharmacology and Physiology, 1980, 7, 367-371.	0.9	1
504	Osmotic fragility of erythrocytes in myopathies. Journal of Neurology, 1981, 224, 253-255.	1.8	1

#	ARTICLE	IF	CITATIONS
505	Opioid Mydriasis: Cross-Tolerance between Morphine and Enkephalins. <i>Pharmacology</i> , 1986, 32, 278-282.	0.9	1
506	Gilles de la Tourette syndrome: EEG and mapping. <i>Psychiatry Research</i> , 1989, 29, 427.	1.7	1
507	Torsion dystonia in jews and non-jews. <i>Annals of Neurology</i> , 1991, 29, 340-340.	2.8	1
508	Evaluation of the Hachinski Ischemic Scale in a Prospective Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 1992, 3, 10-14.	0.7	1
509	Absence of prion protein mutation in bipolar manic-depressive patients. <i>British Journal of Psychiatry</i> , 1992, 161, 132-132.	1.7	1
510	Pupillary responses and blink reflex in myotonic dystrophy. <i>Clinical Autonomic Research</i> , 1992, 2, 17-19.	1.4	1
511	Increased Thromboxane B2 Generation and β_2 -Thromboglobulin Release from Activated Platelets in Myotonic Dystrophy. <i>Platelets</i> , 1993, 4, 45-48.	1.1	1
512	Saccadic responses in patients with hemispheric stroke. <i>Documenta Ophthalmologica</i> , 1994, 85, 267-274.	1.0	1
513	Tolerance to the mydriatic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine in mice. <i>Journal of Anesthesia</i> , 1994, 8, 297-300.	0.7	1
514	Apolipoprotein E4 in Parkinson's disease. <i>Neurology</i> , 1995, 45, 1025.	1.5	1
515	Plasmapheresis in Guillain-Barré syndrome. <i>European Journal of Neurology</i> , 1996, 3, 417-423.	1.7	1
516	Dopamine uptake by platelet storage granules in first-degree relatives of Tourette's syndrome patients. <i>Biological Psychiatry</i> , 1998, 44, 1166-1170.	0.7	1
517	Cortical lesions associated with transient neurological symptoms - not always a matter of cause and effect. <i>European Journal of Neurology</i> , 2003, 10, 721-725.	1.7	1
518	Gastric Dysfunction. , 2005, , 105-113.		1
519	Vascular dementia 2003. <i>Journal of the Neurological Sciences</i> , 2005, 229-230, 1-2.	0.3	1
520	Treatment of advanced Alzheimer's disease with cholinesterase inhibitors. , 2008, 4, 371-372.		1
521	Smoking and amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2010, 67, 694-694.	2.8	1
522	Vascular dementia 2009. <i>Journal of the Neurological Sciences</i> , 2010, 299, 1.	0.3	1

#	ARTICLE	IF	CITATIONS
523	AD: Are we intervening too late?. Journal of Neural Transmission, 2011, 118, 1359-1359.	1.4	1
524	Editorial Comments: Is multiple sclerosis a neurodegenerative or inflammatory disease?. Journal of Neural Transmission, 2013, 120, 1457-1457.	1.4	1
525	Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. , 0, , 76-82.		1
526	Subtype definition of vascular parkinsonism. Parkinsonism and Related Disorders, 2018, 52, 107-108.	1.1	1
527	The Interrelation Between Chronic Headache, Cognitive Scores, and MRI Markers Among Stroke Survivors. Journal of Alzheimer's Disease, 2021, 81, 1555-1566.	1.2	1
528	Dr. Sirota and Colleagues Reply. American Journal of Psychiatry, 2001, 158, 658-658.	4.0	1
529	MRI parameters of Alzheimer's disease in an Arab population of Wadi Ara, Israel. Neuropsychiatric Disease and Treatment, 2005, 1, 77-85.	1.0	1
530	Sexual Dysfunction in Parkinson's Disease. , 2022, , 155-166.		1
531	Transdermal physostigmine-absence of effect on topographic brain mapping. Behavioural Neurology, 1993, 6, 33-5.	1.1	1
532	Bell's palsy with monoclonal gammopathy. Journal of Neurology, 1973, 203, 337-340.	1.8	0
533	Transient Neurogenic Urinary Retention. European Neurology, 1976, 14, 383-385.	0.6	0
534	Diaphragmatic Paralysis. JAMA - Journal of the American Medical Association, 1977, 238, 128.	3.8	0
535	Sex-ratio in chorea associated with systemic lupus erythematosus and hypoparathyroidism. Role of sex hormones. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 1978, 2, 579-584.	0.6	0
536	AGONIST INTERACTION AND DECENTRALIZATION SUPERSENSITIVITY IN THE NICTITATING MEMBRANE OF THE CAT. Clinical and Experimental Pharmacology and Physiology, 1981, 8, 11-16.	0.9	0
537	Effect of Pilocarpine in Ocular Hypotension. Ophthalmic Research, 1985, 17, 72-74.	1.0	0
538	Unilateral thermal anaesthesia. Pain, 1986, 25, 79-82.	2.0	0
539	Antibodies to a 200 kDa cholinergic antigen in Alzheimer's disease. Biochemical Society Transactions, 1988, 16, 855-856.	1.6	0
540	Painful paroxysmal dystonia associated with focal epileptic activity.. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 257-258.	0.9	0

#	ARTICLE	IF	CITATIONS
541	Duration and factors affecting electroencephalogram slowing after generalized tonic-clonic seizures. <i>Journal of Epilepsy</i> , 1995, 8, 193-196.	0.4	0
542	Deprenyl in Parkinson's disease. <i>Annals of Neurology</i> , 1996, 40, 268-269.	2.8	0
543	Saccade Characteristics in Patients with Hemispheric Stroke. <i>Neurorehabilitation and Neural Repair</i> , 1997, 11, 175-180.	1.4	0
544	4-12-02 The presence of apolipoprotein E ϵ 4 allele in Parkinsonian patients does not influence the development of dementia. <i>Journal of the Neurological Sciences</i> , 1997, 150, S226.	0.3	0
545	4-30-02 Movement disorders in prion diseases. <i>Journal of the Neurological Sciences</i> , 1997, 150, S245.	0.3	0
546	P1-092 Human-computer interaction in the administration and analysis of neuropsychological tests – A follow-up study. <i>Neurobiology of Aging</i> , 2004, 25, S121.	1.5	0
547	Toxic exposure and Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006, 247, 242.	0.3	0
548	Chapter 9 GM2 gangliosidosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 82, 171-177.	1.0	0
549	Mortality in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2007, 115, 367-367.	1.0	0
550	2nd World Congress on Controversies in Neurology. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 317-318.	1.4	0
551	Commentary on "A roadmap for the prevention of dementia II: Leon Thal Symposium 2008." – Comments from abroad. , 2009, 5, 157-158.		0
552	Sick patient, normal tests. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2010, 103, 117-119.	0.2	0
553	Current conceptions of the etiology and risk factors for Alzheimer's disease and their possible implications on the design of dementia clinical trials. <i>Clinical Investigation</i> , 2011, 1, 1491-1503.	0.0	0
554	Sexual function in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 70-70.	1.0	0
555	CONy: a new perspective for readers of JNT. <i>Journal of Neural Transmission</i> , 2011, 118, 179-179.	1.4	0
556	Editorial comments. <i>Journal of Neural Transmission</i> , 2011, 118, 605-605.	1.4	0
557	Editorial comments: treatment of motor fluctuations in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2011, 118, 905-906.	1.4	0
558	Editorial comment: is essential tremor a neurodegenerative disease?. <i>Journal of Neural Transmission</i> , 2012, 119, 1373-1373.	1.4	0

#	ARTICLE	IF	CITATIONS
559	JNT Special Issue MDPD Congress, Berlin 2012. Journal of Neural Transmission, 2013, 120, 507-507.	1.4	0
560	International Congress on Vascular Dementia, Athens, Greece, 17â€“20 October 2013. Journal of Alzheimer's Disease, 2014, 42, S1-S1.	1.2	0
561	Mental Dysfunction in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 129-129.	1.5	0
562	Quantitative analysis of phenotypic elements augments traditional electroclinical classification of common familial epilepsies. Epilepsia, 2019, 60, 2194-2203.	2.6	0
563	Reply to Possible Duplicate Publication. Journal of Clinical Psychopharmacology, 2002, 22, 233.	0.7	0
564	Oculopharyngeal Muscular Dystrophy. , 2003, , 662-665.		0
565	Creutzfeldt-Jakob Disease (CJD) is Not an Infectious Disease. Advances in Behavioral Biology, 1995, , 87-93.	0.2	0
566	Abstract TP460: Dominant Imaging Markers for Post Stroke Cognitive Performance in the TABASCO Study. Stroke, 2016, 47, .	1.0	0
567	Vascular Parkinsonism. , 2017, , 233-247.		0
568	Neuropathology of Non-Motor Parkinsonâ€™s Disease Symptoms. , 2022, , 35-45.		0
569	Autonomic Dysfunction and Failure in Parkinsonâ€™s Disease. , 2022, , 130-144.		0